公开(公告)号：US20190308949A1

公开(公告)日：2019-10-10

申请号：US16340685

申请日：2017-10-09

Applicant: Development Center for Biotechnology

Inventor： Shao-Zheng Peng ,  Chu-Bin Liao ,  Hung-Kai Chen ,  Chen-Hsuan Ho ,  Hung-Jyun Huang ,  Shian-Yi Chiou

IPC: C07D401/12 ,  C07D401/14 ,  C07D241/52 ,  C07D413/04 ,  C07D413/14 ,  A61P35/00

Abstract: A compound, capable of inhibiting kinases, for the treatments of diseases or disorders mediated by such kinases, has a structure of formula (I): or a stereoisomer, a tautomer, a pharmaceutically acceptable salt thereof. The compound can be used in the treatments of diseases or conditions mediated by CSF-1R, c-KIT, FLT3, or PDGFR kinases. Such diseases or conditions may include cancers, autoimmune diseases, and bone resorptive diseases.

公开(公告)号：US12043668B2

公开(公告)日：2024-07-23

申请号：US17413496

申请日：2019-12-13

Applicant: DEVELOPMENT CENTER FOR BIOTECHNOLOGY

Inventor： Chen-Hsuan Ho ,  Chu-Bin Liao ,  Yu-Kai Chen ,  Chen-Wei Huang ,  Tze-Ping Yang ,  Szu-Liang Lai

IPC: C07K16/28 ,  A61P35/00

CPC classification number: C07K16/2866 ,  A61P35/00 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92

Abstract: An antibody, or an antigen-binding fragment thereof, that binds specifically to human CSF-1R includes a heavy chain variable domain that contains a HCDR1 region having the sequence of SEQ ID NO: 4, a HCDR2 region having the sequence of SEQ ID NO: 5, and a HCDR3 region having the sequence of SEQ ID NO: 6; and a light chain variable domain that contains a LCDR1 region having the sequence of SEQ ID NO: 7, a LCDR2 region having the sequence of SEQ ID NO: 8, and a LCDR3 region having the sequence of SEQ ID NO: 9. The heavy chain variable domain comprises the sequence of SEQ ID NO: 2, and wherein the light chain variable domain comprises the sequence of SEQ ID NO: 3.

公开(公告)号：US10689362B2

公开(公告)日：2020-06-23

申请号：US16340685

申请日：2017-10-09

Applicant: Development Center for Biotechnology

Inventor： Shao-Zheng Peng ,  Chu-Bin Liao ,  Hung-Kai Chen ,  Chen-Hsuan Ho ,  Hung-Jyun Huang ,  Shian-Yi Chiou

IPC: A61K31/44 ,  A61K31/498 ,  A61P35/00 ,  C07D241/40 ,  C07D241/44 ,  C07D401/06 ,  C07D401/12 ,  C07D241/52 ,  C07D401/14 ,  C07D413/04 ,  C07D413/14 ,  C07D401/04 ,  C07D413/12 ,  C07D403/04 ,  C07D405/12 ,  C07D409/12 ,  C07D403/12 ,  C07D403/14

Abstract: A compound, capable of inhibiting kinases, for the treatments of diseases or disorders mediated by such kinases, has a structure of formula (I): or a stereoisomer, a tautomer, a pharmaceutically acceptable salt thereof. The compound can be used in the treatments of diseases or conditions mediated by CSF-1R, c-KIT, FLT3, or PDGFR kinases. Such diseases or conditions may include cancers, autoimmune diseases, and bone resorptive diseases.